Study of FAECC Scale (Modified FLACC) to Evaluate Ear Pain in Children With Acute Otitis Media

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Arbor Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01588535
First received: April 27, 2012
Last updated: December 3, 2013
Last verified: December 2013

April 27, 2012
December 3, 2013
May 2012
August 2012   (final data collection date for primary outcome measure)
Consistency of primary assessor and caregiver FAECC scores using Pearson's correlation coefficient [ Time Frame: up to 120 minutes after first dose and Day 4 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01588535 on ClinicalTrials.gov Archive Site
reduction in pain scores from predose to each post-dose time point [ Time Frame: up to 120 minutes after each dose ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study of FAECC Scale (Modified FLACC) to Evaluate Ear Pain in Children With Acute Otitis Media
Phase 2, Multicenter, Placebo-controlled, Double-masked, Randomized Study to Demonstrate Reliability and Validity of FAECC Scale (Modified FLACC) to Evaluate Relief of Pain in Subjects With Acute Otitis Media Aged >/=2 Months to <5 Years

This study is to assess the reliability and validity of the FAECC scale to evaluate pain associated with acute otitis media in children aged 2 months to 5 years.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
  • Pain
  • Otitis Media
  • Drug: benzocaine
    benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
    Other Name: Arbor otic
  • Drug: placebo
    placebo solution, five drops in affected ear canal each hour as needed
    Other Name: Arbor Otic
  • Active Comparator: benzocaine solution
    Intervention: Drug: benzocaine
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
August 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The patient has age in the interval 2 months ≤ age < 5.00 years, signs and symptoms of AOM, and moderate to severe pain (current episode ≤ 2 weeks duration). Moderate to severe pain is defined as a score of > or = 4 (on a scale of 0 - 10) for the FAECC scale as assessed by the primary assessor.
  • The patient's parent/guardian must have read and signed the written informed consent prior to study participation.
  • The patient is normally active and otherwise judged to be in good health on the basis of medical history and limited physical examination.

Exclusion Criteria:

  • Patient has perforated tympanic membrane, history of a perforated tympanic membrane in the last 6 months, or if a perforated tympanic membrane could not be ruled out by speculum examination, impedance testing tympanometry, pneumatic otoscopy, or Valsalva maneuver. Patients who are subsequently diagnosed with a perforated membrane during treatment are to be discontinued immediately. Patients with tympanostomy tubes are not allowed.
  • Patient has acute or chronic otitis externa.
  • Patient has chronic otitis media (current episode ≥ 2 weeks).
  • Patient has seborrheic dermatitis involving the affected external ear canal or pinna.
  • Patient has received any otic topical or systemic antibiotic within 14 days prior to study entry (topical or systemic antibiotics for acne will be allowed on a chronic basis for subjects who have been on a stable dose for at least 14 days prior to entry).
  • Patient has received any topical drying agent or over-the-counter therapy for otitis media within 36 hours prior to enrollment.
  • Patient has fever ≤ 102.0 F (oral or equivalent).
  • Patient has known hypersensitivity to the study drug or similar compounds including any of the inactive ingredients.
  • Patient is receiving medication on a chronic basis for pain (including steroidal or non steroidal anti-inflammatory drugs) and has not been on a stable dose for at least 1 month prior to entry into the study.
  • Patient has clinically significant mental illness (to be determined by the Investigator).
  • Patient has been exposed to any investigational agent within 30 days prior to study entry.
  • Patient has been previously enrolled in this study.
  • Patient or caregiver (parent/guardian) has a condition the Investigator believes will interfere with the ability to provide consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk.
  • Patient has a glucose 6-phosphate dehydrogenase deficiency or is taking concomitant medications associated with methemoglobinemia (such as nitrates or nitrites; aniline dyes; or medications, including lidocaine, prilocaine, phenazopyridine hydrochloride [Pyridium], and others).
  • Patient demonstrates clinical signs of anemia. The absolute amount of deoxygenated or abnormal hemoglobin (rather than its percentage) is required for cyanosis to be clinically evident. Patients with moderate-to-severe anemia may not appear cyanotic, even with elevated percentages of deoxygenated or abnormal hemoglobin.
  • Patient has congenital (i.e., hereditary) methemoglobinemia.
  • Patient has a recent history of acute gastroenteritis within 14 days prior to study entry. An association between methemoglobinemia and acute gastroenteritis in infants has been noted in several studies and may be due to acidosis from stool bicarbonate loss impairing the already immature function of the methemoglobin reductase system in these young patients.
Both
2 Months to 4 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01588535
AR01.004
No
Arbor Pharmaceuticals, Inc.
Arbor Pharmaceuticals, Inc.
Not Provided
Study Director: Laurence Downey, MD Arbor Pharmaceuticals, Inc.
Arbor Pharmaceuticals, Inc.
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP